Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
TRPV Channels Market: Competitive Landscape, Pipeline, and Market Analysis 2023
TRPV Channels Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Transient Receptor Potential Vanilloid (TRPV) channel is a subfamily of the TRP family of receptors that are animal cation channels. TRPV subfamily has six members – TRPV1, TRPV2, TRPV3, TRPV4, TRPV5, and TRPV6. TRPV1-4 have non-selective cation conducting pores, while TRPV5 & 6 are calcium selective. TRPV1 is highly expressed in sensory neurons and is activated by Capsaicin, Protons, Toxins, and temperature above 42?C. It is physiologically essential for thermal perception and chemical nociception. TRPV2 has been associated with diseases like cancer. TRPV3 is associated with skin health and has gained importance due to it. TRPV4 has osmoregulation and mechano-transduction roles in the body. Both TRPV5 & TRPV6 are present in the apical membrane of the epithelial cells and act as a gateway for Ca2+ during absorption and reabsorption. TRPV5 is highly expressed in the kidney, while TRPV6 is expressed in various organs, including the intestine and placenta. Hence, these receptors play a very crucial role in the physiological roles of our body. Companies are trying to find new and novel molecules to prevent and cure these diseases. The development and launch of newer products by the market players will significantly enhance the revenue of the TRPV channels market over the forecast years. According to a research article, in 2022, about 3-17% of the population will suffer from Neuropathic pain.
Several of these inhibitors are on the market, while many are in ongoing clinical trials. companies have various products in their pipelines, with 52 products in various stages of clinical trials. 1 product is in Phase 4, 8 products are in Phase 3, 19 products are in Phase 2, and 5 products are in Phase 1 of the clinical trials.
Key Developments of TRPV channels
Clinical Activity and Developments of TRPV Channels
As of June 2023, companies have approximately 52 products for 178 diseases. For these diseases, many trials are being conducted by players globally. For instance,
Approved molecules
Drugs in Pipeline
|
Molecule name |
Number of studies |
|
Qutenza (capsaicin) |
46 |
|
Adlea (capsaicin) |
19 |
|
Asivatrep (PAC-14028) |
12 |
|
AZD1386 |
11 |
|
SB-705498 |
11 |
Qutenza (8% Capsaicin), an agonist of TPRV Channels by Grunenthal, is marketed globally in many markets, including the USA, Europe, Canada, and others. It is indicated for treating neuropathic pain associated with Diabetic Peripheral Neuropathy (DPN) of the feet in adults. It is also in the clinical trials for many other indications like neuropathies, including Diabetic Neuropathy, neuralgia, viral infections, and Peripheral Nerve Injuries in the later stages of the clinical trials. Resiniferatoxin (MCP-101), a potent functional analogue of capsaicin, has been designated a Breakthrough therapy for pain associated with knee osteoarthritis. It is in the 3rd phase of the clinical trial for many indications while also being evaluated for other indications.
Qutenza (Capsaicin) had a net sale of $2816 million in the financial year 2021. Qutenza sales increased by 310% in the financial year 2021 compared to the financial year 2020. Therefore, there is a rising demand for the treatment across the globe as the prevalence of Diabetes and its associated Neuropathic pain has been increasing globally. According to a research study in 2019, the prevalence rate of peripheral neuropathy in adults is estimated to be between 6% to 51%. The symptom depends upon many factors such as age, type of diabetes, glucose control, duration of diabetes, and others. According to CDC, the prevalence of any form of arthritis in the USA is 54.4 million in 2020, while osteoarthritis, which is the most common form of arthritis, affects nearly 32.5 million US adults. Therefore, there is an opportunity in the TRPV Channel market for the players to launch new products globally.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Qutenza (8% Capsaicin) is approved by the FDA, while resiniferatoxin (MCP-101) has received Breakthrough Therapy designation from the FDA.
These are used in various indications like Peripheral Neuropathic Pain, Peripheral pain associated with osteoarthritis of the knee Diabetic Peripheral Neuropathy, and others.
Grunenthal (Germany), LTS Lohmann Therapy Systems AG (Germany), Arcion Therapeutics Inc (USA), Centrexion Therapeutics (Boston), and Amorepacific Corporation (South Korea) are some of the major market players for TRPV Channels.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to Diabetes Mellitus and nerve injuries and associated pain are the key opportunities for TRPV channels in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.